Brief: Resverlogix randomizes first patient in Taiwan portion of Betonmace clinical trial
10/07/2017 12:00
July 10 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix randomizes first patient in Taiwan/China
portion of the phase 3 Betonmace clinical trial
* As a result of randomization hepalink is now responsible
for first c$1 million payment to Resverlogix
* Co to be eligible to sales-based milestone payments from
Hepalink when Apabetalone reaches annual sales milestones in
territories
* Each sales-based milestone ranging from $5 million to $90
million
Source text for Eikon: ID:nCNWT29qda
Further company coverage: RVX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment